[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641585":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":28,"interventions":34,"overallOfficials":21,"centralContacts":21,"locations":21,"responsibleParty":40,"collaborators":42,"id":45,"slug":21,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":21,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":21,"enrollmentInfo":53,"targetDuration":21,"studyType":56,"phases":57,"briefSummary":58,"conditions":59,"keywords":21,"overallStatus":61,"whyStopped":21,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":21},{"fullName":5,"class":6},"YSLab","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Improvement of the nasal dryness symptoms","The changes between the baseline and day 7 will be assessed using the Rhinitis Sicca Symptom Score (RSSS). The RSSS is constituted by the sum of the following individual symptoms: sensation of dry nose, impairment of nasal breathing\u002Fnasal obstruction, crusting, itching\u002Fsneezing attacks, pain in the nose, anterior nasal discharge \u002Frunny nose, thick nasal discharge, desire to clear one's throat\u002F dry throat, impairment of smell and impairment of sleep. Patients assessed with each of these symptoms on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).","Day 0 - Day 0 immediately after first use - Day 7",[14,17],{"measure":15,"description":16,"timeFrame":12},"Improvement of the total perceive Nasal symptom relief","The changes between the baseline and day 7 in the rhinoscopy score will be assessed. The rhinoscopy score is constituted by the sum of the following symptom: dryness, atrophy, redness, oedema of the nasal mucosa and crusting. The clinician will assess each symptom on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).",{"measure":18,"description":19,"timeFrame":20},"Incidence of Adverse Events","Adverse events, if any, will be tabulated by the investigator","through study completion, an average of 7 days",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"NA","SINGLE_GROUP","TREATMENT",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE",[29],{"label":30,"type":31,"description":21,"interventionNames":32},"Nasal spray","EXPERIMENTAL",[33],"Device: Spray pompe nasal",[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":21},"DEVICE","Spray pompe nasal","Dosage: 2 sprays per nostril",[30],{"type":41,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[43],{"name":44,"class":6},"Eurofins","100641585",false,"NCT07657247","Clinical Evaluation of the Efficacy of a Nasal Spray in the Treatment of Nasal Dryness","Clinical Evaluation of the Efficacy of a Nasal Spray Based on Isotonic Seawater and Hyaluronic Acid in the Treatment of Nasal Dryness","Inclusion Criteria:\n\n* Gender: female and\u002For male.\n* Age: adults and children from 6 years old:\n* The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6.\n* Subjects agree to refrain from taking any medication and\u002For taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen.\n* Autonomous adult, or minor with the consent of their legal representative.\n* Subject and\u002For Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject and\u002For Parent\u002Flegal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.\n* Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use.\n* Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.\n\nExclusion Criteria:\n\n* Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study.\n* Subjects using other nasal sprays, nasal pumps, nasal irrigation\u002Frinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study.\n* Subjects with a history of sensitivity to products related to the product being evaluated.\n* Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and\u002For participation in the study.\n* Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.\n* Person refusing to sign the informed consent form prior to the study.\n* Person participating or having participated in any other clinical study within the 30 days preceding the study.\n* Person participating in any other clinical study.","ALL","6 Years",{"count":54,"type":55},60,"ESTIMATED","INTERVENTIONAL",[23],"The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.",[60],"Nasal Dryness","NOT_YET_RECRUITING","2026-06-12",{"date":64,"type":65},"2026-06-18","ACTUAL",{"date":67,"type":55},"2026-12-15",{"date":69,"type":55},"2027-03",{"name":5,"class":6}]